Acorda Therapeutics Inc

NASDAQ:ACOR  
4.74
+0.05 (+1.07%)
Layoffs, Officer Changes, Other Pre-Announcement

Acorda Announces 15% Reduction In Headcount, Management Changes

Published: 09/09/2021 12:27 GMT
Acorda Therapeutics Inc (ACOR) - Acorda Therapeutics Announces Corporate Restructuring, Management Changes.
Acorda Therapeutics Inc - 15% Reduction in Headcount.
Acorda Therapeutics Inc - Greater Than $20 Million in Expected Annualized Cost Savings From Headcount and Budget Reductions.
Acorda Therapeutics Inc - Most of Reduction in Personnel Will Take Place Immediately, With Balance Completed in Q1 of 2022.
Acorda Therapeutics Inc - Greater Than $20 Million in Expected Annualized Cost Savings From Headcount and Budget Reductions.
Acorda Therapeutics Inc - Lauren Sabella, Currently Acorda's Chief Commercial Officer, Has Been Named Chief Operating Officer.
Acorda Therapeutics Inc - Expects to Realize Annualized Cost Savings of About $20 Million, Beginning in 2022.
Acorda Therapeutics Inc - Kerry Clem, Acorda's Executive Vice President of Sales, Market Access, and Operations, Has Been Named Chief Commercial Officer.